[HTML][HTML] CAR-T cell therapy in hematological malignancies: current opportunities and challenges
X Zhang, L Zhu, H Zhang, S Chen, Y Xiao - Frontiers in immunology, 2022 - frontiersin.org
Chimeric antigen receptor T (CAR-T) cell therapy represents a major breakthrough in cancer
treatment, and it has achieved unprecedented success in hematological malignancies …
treatment, and it has achieved unprecedented success in hematological malignancies …
[HTML][HTML] Engineering CAR-T cells for next-generation cancer therapy
M Hong, JD Clubb, YY Chen - Cancer cell, 2020 - cell.com
T cells engineered to express chimeric antigen receptors (CARs) with tumor specificity have
shown remarkable success in treating patients with hematologic malignancies and …
shown remarkable success in treating patients with hematologic malignancies and …
[HTML][HTML] Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trial
There is a pressing need for allogeneic chimeric antigen receptor (CAR)-immune cell
therapies that are safe, effective and affordable. We conducted a phase 1/2 trial of cord …
therapies that are safe, effective and affordable. We conducted a phase 1/2 trial of cord …
Loss of metabolic fitness drives tumor resistance after CAR-NK cell therapy and can be overcome by cytokine engineering
Chimeric antigen receptor (CAR) engineering of natural killer (NK) cells is promising, with
early-phase clinical studies showing encouraging responses. However, the transcriptional …
early-phase clinical studies showing encouraging responses. However, the transcriptional …
[HTML][HTML] Engineering strategies to overcome the current roadblocks in CAR T cell therapy
S Rafiq, CS Hackett, RJ Brentjens - Nature reviews Clinical oncology, 2020 - nature.com
T cells genetically engineered to express chimeric antigen receptors (CARs) have proven—
and impressive—therapeutic activity in patients with certain subtypes of B cell leukaemia or …
and impressive—therapeutic activity in patients with certain subtypes of B cell leukaemia or …
KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape
Trogocytosis is an active process that transfers surface material from targeted to effector
cells. Using multiple in vivo tumor models and clinical data, we report that chimeric antigen …
cells. Using multiple in vivo tumor models and clinical data, we report that chimeric antigen …
[HTML][HTML] Cancer therapy with TCR-engineered T cells: current strategies, challenges, and prospects
To redirect T cells against tumor cells, T cells can be engineered ex vivo to express cancer-
antigen specific T cell receptors (TCRs), generating products known as TCR-engineered T …
antigen specific T cell receptors (TCRs), generating products known as TCR-engineered T …
Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors
E Liu, D Marin, P Banerjee… - … England Journal of …, 2020 - Mass Medical Soc
Background Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy has shown
remarkable clinical efficacy in B-cell cancers. However, CAR T cells can induce substantial …
remarkable clinical efficacy in B-cell cancers. However, CAR T cells can induce substantial …
Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management
JN Brudno, JN Kochenderfer - Blood reviews, 2019 - Elsevier
Chimeric antigen receptor (CAR) T-cell therapy is an effective new treatment for hematologic
malignancies. Two CAR T-cell products are now approved for clinical use by the US FDA …
malignancies. Two CAR T-cell products are now approved for clinical use by the US FDA …
[HTML][HTML] Current progress in CAR-T cell therapy for solid tumors
Cancer immunotherapy by chimeric antigen receptor-modified T (CAR-T) cells has shown
exhilarative clinical efficacy for hematological malignancies. Recently two CAR-T cell based …
exhilarative clinical efficacy for hematological malignancies. Recently two CAR-T cell based …